DaVita (DVA) – Research Analysts’ Weekly Ratings Updates

DaVita (NYSE: DVA) recently received a number of ratings updates from brokerages and research firms:

• 8/7/2026 – DaVita was upgraded by TD Cowen from “hold” to “buy”. They now have a $220.00 price target on the stock, up from $201.00.
• 8/7/2026 – DaVita was given a new $220.00 price target by Oppenheimer Holdings, Inc..
• 8/7/2026 – DaVita was given a new $220.00 price target by Raymond James Financial, Inc..
• 8/7/2026 – DaVita had its price target lowered by Truist Financial Corporation from $250.00 to $215.00. They now have a “hold” rating on the stock.
• 8/5/2026 – DaVita was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/5/2026 – DaVita had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $265.00 price target on the stock.
• 8/5/2026 – DaVita had its price target raised by Barclays PLC from $218.00 to $224.00. They now have an “equal weight” rating on the stock.
• 7/14/2026 – DaVita had its price target raised by Truist Financial Corporation from $205.00 to $250.00. They now have a “hold” rating on the stock.
• 7/10/2026 – DaVita had its price target raised by UBS Group AG from $235.00 to $270.00. They now have a “buy” rating on the stock.
• 7/8/2026 – DaVita had its price target raised by Barclays PLC from $194.00 to $218.00. They now have an “equal weight” rating on the stock.
• 7/6/2026 – DaVita was downgraded by Zacks Research from “strong-buy” to “hold”.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.